Nidorf M - Search Results

1

Hyperhomocysteinemia but not the C677T mutation of methylenetetrahydrofolate reductase is an independent risk determinant of carotid wall thickening. The Perth Carotid Ultrasound Disease Assessment Study (CUDAS).

McQuillan BM, Beilby JP, Nidorf M, Thompson PL, Hung J. McQuillan BM, et al. Among authors: nidorf m. Circulation. 1999 May 11;99(18):2383-8. doi: 10.1161/01.cir.99.18.2383. Circulation. 1999. PMID: 10318658

2

Angiotensin-converting enzyme gene polymorphism and carotid wall thickening in a community population.

Hung J, McQuillan BM, Nidorf M, Thompson PL, Beilby JP. Hung J, et al. Among authors: nidorf m. Arterioscler Thromb Vasc Biol. 1999 Aug;19(8):1969-74. doi: 10.1161/01.atv.19.8.1969. Arterioscler Thromb Vasc Biol. 1999. PMID: 10446079

3

Antioxidant vitamins and the risk of carotid atherosclerosis. The Perth Carotid Ultrasound Disease Assessment study (CUDAS).

McQuillan BM, Hung J, Beilby JP, Nidorf M, Thompson PL. McQuillan BM, et al. Among authors: nidorf m. J Am Coll Cardiol. 2001 Dec;38(7):1788-94. doi: 10.1016/s0735-1097(01)01676-x. J Am Coll Cardiol. 2001. PMID: 11738275 Free article.

4

Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease.

Nidorf M, Thompson PL. Nidorf M, et al. Am J Cardiol. 2007 Mar 15;99(6):805-7. doi: 10.1016/j.amjcard.2006.10.039. Epub 2007 Jan 16. Am J Cardiol. 2007. PMID: 17350370 Clinical Trial.

5

Assessment of LV mass by echocardiography.

Nidorf M, McQuillan B. Nidorf M, et al. Circulation. 1999 Jan 5-12;99(1):165-6. Circulation. 1999. PMID: 9884395 No abstract available.

6

Coronary thrombolysis: an important therapy for myocardial infarction.

Nidorf M, Thompson PL. Nidorf M, et al. Med J Aust. 1988 Oct 3;149(7):376-80. doi: 10.5694/j.1326-5377.1988.tb120674.x. Med J Aust. 1988. PMID: 3050397 Review. No abstract available.

7

Coronary thrombolysis.

Thompson PL, Nidorf M. Thompson PL, et al. Among authors: nidorf m. Med J Aust. 1989 Apr 17;150(8):466-7. Med J Aust. 1989. PMID: 2497312 No abstract available.

8

Consensus Statement Regarding the Efficacy and Safety of Long-Term Low-Dose Colchicine in Gout and Cardiovascular Disease.

Robinson PC, Terkeltaub R, Pillinger MH, Shah B, Karalis V, Karatza E, Liew D, Imazio M, Cornel JH, Thompson PL, Nidorf M. Robinson PC, et al. Among authors: nidorf m. Am J Med. 2022 Jan;135(1):32-38. doi: 10.1016/j.amjmed.2021.07.025. Epub 2021 Aug 18. Am J Med. 2022. PMID: 34416165 Free PMC article. Review.

9

Refining the risk-benefit equation for thrombolysis: how to identify the low risk patient before administering thrombolytic therapy.

Nidorf M, Parsons R, Thompson P, Jamrozik K, Hobbs M. Nidorf M, et al. Aust N Z J Med. 1998 Aug;28(4):525-8. doi: 10.1111/j.1445-5994.1998.tb02104.x. Aust N Z J Med. 1998. PMID: 9777133

10

Effect of colchicine compared with placebo on high sensitivity C-reactive protein in patients with acute coronary syndrome or acute stroke: a pilot randomized controlled trial.

Raju NC, Yi Q, Nidorf M, Fagel ND, Hiralal R, Eikelboom JW. Raju NC, et al. Among authors: nidorf m. J Thromb Thrombolysis. 2012 Jan;33(1):88-94. doi: 10.1007/s11239-011-0637-y. J Thromb Thrombolysis. 2012. PMID: 21918905 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

18 results

Search Page

Filters